Name | Number of supported studies | Average coverage | |
---|---|---|---|
erythrocyte | 4 studies | 32% ± 7% |
Insufficient scRNA-seq data for expression of PHOSPHO1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 89% | 131.44 | 2357 / 2642 | 73% | 2.33 | 516 / 705 |
kidney | 85% | 85.84 | 76 / 89 | 62% | 1.54 | 562 / 901 |
lung | 99% | 222.81 | 572 / 578 | 42% | 1.17 | 490 / 1155 |
adrenal gland | 84% | 61.79 | 217 / 258 | 33% | 2.77 | 75 / 230 |
prostate | 86% | 78.10 | 210 / 245 | 22% | 0.37 | 108 / 502 |
spleen | 100% | 829.49 | 241 / 241 | 0% | 0 | 0 / 0 |
thymus | 76% | 65.85 | 499 / 653 | 23% | 0.45 | 140 / 605 |
peripheral blood | 98% | 10574.35 | 912 / 929 | 0% | 0 | 0 / 0 |
ovary | 17% | 11.42 | 30 / 180 | 77% | 7.57 | 330 / 430 |
esophagus | 39% | 27.90 | 563 / 1445 | 50% | 1.15 | 92 / 183 |
uterus | 61% | 46.18 | 103 / 170 | 28% | 1.02 | 130 / 459 |
intestine | 50% | 42.17 | 485 / 966 | 37% | 0.82 | 193 / 527 |
stomach | 33% | 22.09 | 120 / 359 | 51% | 1.14 | 146 / 286 |
muscle | 78% | 154.53 | 627 / 803 | 0% | 0 | 0 / 0 |
breast | 58% | 40.02 | 266 / 459 | 19% | 0.60 | 214 / 1118 |
heart | 75% | 60.90 | 649 / 861 | 0% | 0 | 0 / 0 |
adipose | 66% | 64.39 | 797 / 1204 | 0% | 0 | 0 / 0 |
bladder | 38% | 24.76 | 8 / 21 | 22% | 0.55 | 110 / 504 |
tonsil | 0% | 0 | 0 / 0 | 58% | 1.35 | 26 / 45 |
liver | 46% | 29.95 | 103 / 226 | 4% | 0.06 | 16 / 406 |
lymph node | 0% | 0 | 0 / 0 | 48% | 3.08 | 14 / 29 |
pancreas | 5% | 3.88 | 17 / 328 | 43% | 0.77 | 76 / 178 |
skin | 14% | 8.86 | 250 / 1809 | 13% | 0.22 | 62 / 472 |
blood vessel | 24% | 20.77 | 325 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 9% | 0.13 | 7 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030500 | Biological process | regulation of bone mineralization |
GO_0035630 | Biological process | bone mineralization involved in bone maturation |
GO_0001958 | Biological process | endochondral ossification |
GO_0030282 | Biological process | bone mineralization |
GO_0065010 | Cellular component | extracellular membrane-bounded organelle |
GO_0005829 | Cellular component | cytosol |
GO_0031012 | Cellular component | extracellular matrix |
GO_0052732 | Molecular function | phosphoethanolamine phosphatase activity |
GO_0016791 | Molecular function | phosphatase activity |
GO_0016462 | Molecular function | pyrophosphatase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0052731 | Molecular function | phosphocholine phosphatase activity |
Gene name | PHOSPHO1 |
Protein name | Phosphoethanolamine/phosphocholine phosphatase 1 Phosphoethanolamine/phosphocholine phosphatase (EC 3.1.3.75) |
Synonyms | |
Description | FUNCTION: Phosphatase that has a high activity toward phosphoethanolamine (PEA) and phosphocholine (PCho) . Involved in the generation of inorganic phosphate for bone mineralization (By similarity). Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (By similarity). . |
Accessions | D6RHH9 ENST00000503902.1 D6RB58 Q8TCT1 ENST00000512250.1 ENST00000514112.1 [Q8TCT1-3] ENST00000413580.5 [Q8TCT1-3] I3L4N1 ENST00000574638.1 D6RIT6 ENST00000310544.9 [Q8TCT1-1] ENST00000511066.5 |